Synaptic fatigue is more pronounced in the APP/PS1 transgenic mouse model of Alzheimer's disease

Current Alzheimer Research

Volumn 2, Issue 2, 2005, Pages 137-140

  Zhang, Hong ^a   Gong, Bing ^a   Liu, Shumin ^a   Fa', Mauro ^a   Ninan, Ipe ^a   Staniszewski, Agnieszka ^a   Arancio, Ottavio ^a,b  

^a NewYork Presbyterian Hospital   (United States)

^b Physicians and Surgeons Bldg 12 445 ^*  (United States)

Author keywords

Alzheimer's disease; Amyloid; Neurotransmitter release; Paired pulse facilitation; Post tetanic potentiation; Synapse; Synaptic fatigue

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; PRESENILIN 1;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CONFERENCE PAPER; CONTROLLED STUDY; FACILITATION; GENE OVEREXPRESSION; HIPPOCAMPUS; MOUSE; NEUROTRANSMITTER RELEASE; NONHUMAN; POST TETANIC POTENTIATION; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; SYNAPTIC TRANSMISSION; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; DISEASE MODELS, ANIMAL; EXCITATORY POSTSYNAPTIC POTENTIALS; HIPPOCAMPUS; HUMANS; MEMBRANE PROTEINS; MICE; MICE, TRANSGENIC; PRESENILIN-1; SYNAPSES;

EID: 20844443826     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/1567205053585936     Document Type: Conference Paper

References (41)

1. Selkoe DJ. Normal and abnormal biology of the beta-amyloid precursor protein. Annu Rev Neurosci 17: 489-517 (1994).
2. Arendash GW, King DL, Gordon MN, Morgan D, Hatcher JM, Hope CE, et al. Progressive, age-related behavioral impairments in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes. Brain Res 891: 42-53 (2001).
3. Chapman PF, White GL, Jones MW, Cooper-Blacketer D, Marshall VJ, Irizarry M, et al. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat Neurosci 2: 271-276 (1999).
4. Dineley KT, Xia X, Bui D, Sweatt JD and Zheng H. Accelerated plaque accumulation, associative learning deficits and upregulation of alpha 7 nicotinic receptor protein in transgenic mice co-expressing mutant human presenilin 1 and amyloid precursor proteins. J Biol Chem 277: 22768-22780 (2002).
5. Dodart JC, Meziane H, Mathis C, Bales KR, Paul SM and Ungerer A. Behavioral disturbances in transgenic mice overexpressing the V717F beta-amyloid precursor protein. Behav Neurosci 113: 982-990 (1999).
6. Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, Jantzen P, et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med 4: 97-100 (1998).
7. Holcomb LA, Gordon MN, Jantzen P, Hsiao K, Duff K and Morgan D. Behavioral changes in transgenic mice expressing both amyloid precursor protein and presenilin-1 mutations: lack of association with amyloid deposits. Behav Genet 29: 177-185 (1999).
8. King DL, Arendash GW, Crawford F, Sterk T, Menendez J and Mullan MJ. Progressive and gender-dependent cognitive impairment in the APP(SW) transgenic mouse model for Alzheimer's disease. Behav Brain Res 103: 145-162 (1999).
9. Sant'Angelo A, Trinchese F and Arancio O. Usefulness of behavioral and electrophysiological studies in transgenic models of Alzheimer's disease. Neurochem Res 28: 1009-1015 (2003).
10. Trinchese F, Liu S, Battaglia F, Walter S, Mathews PM and Arancio O. Progressive age-related development of Alzheimer-like pathology in APP/PS1 mice. Ann Neurol 55: 801-814 (2004a).
11. Westerman MA, Cooper-Blacketer D, Mariash A, Kotilinek L, Kawarabayashi T, Younkin LH, et al. The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. J Neurosci 22: 1858-1867 (2002).
12. Cullen WK, Suh YH, Anwyl R and Rowan MJ. Block of LTP in rat hippocampus in vivo by beta-amyloid precursor protein fragments. Neuroreport 8: 3213-3217 (1997).
13. Itoh A, Akaike T, Sokabe M, Nitta A, Iida R, Olariu A, et al. Impairments of long-term potentiation in hippocampal slices of beta-amyloid-infused rats. Eur J Pharmacol 382: 167-175 (1999).
14. Vitolo OV, Sant'Angelo A, Costanzo V, Battaglia F, Arancio O and Shelanski M. Amyloid beta-peptide inhibition of the PKA/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling. Proc Natl Acad Sci USA 99: 13217-13221 (2002).
15. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416: 535-539 (2002).
16. Ferrer I, Marti E, Tortosa A and Blasi J. Dystrophic neurites of senile plaques are defective in proteins involved in exocytosis and neurotransmission. J Neuropathol Exp Neurol 57: 218-225 (1998).
17. Tomlinson BE, Corsellis JAN. Aging and the dementias. In: Greenfield's Neuropathology, 4th ed. (Eds: Adams JH, Corsellis JAN, Duchen LW), John Wiley & Sons, New York, p. 951-1025, 1984.
18. Cole GM, Masliah E, Shelton ER, Chan HW, Terry RD and Saitoh T. Accumulation of amyloid precursor fragment in Alzheimer plaques. Neurobiol Aging 12: 85-91 (1991).
19. Joachim C, Games D, Morris J, Ward P, Frenkel D and Selkoe D. Antibodies to non-beta regions of the beta-amyloid precursor protein detect a subset of senile plaques. Am J Pathol 138: 373-384 (1991).
20. Masliah E, Mallory M, Hansen L, Alford M, DeTeresa R, Terry R, Baudier J, et al. Localization of amyloid precursor protein in GAP43-immunoreactive aberrant sprouting neurites in Alzheimer's disease. Brain Res 574: 312-316 (1992).
21. Shoji M, Hirai S, Yamaguchi H, Harigaya Y and Kawarabayashi T. Amyloid beta-protein precursor accumulates in dystrophic neurites of senile plaques in Alzheimer-type dementia. Brain Res 512: 164-168 (1990).
22. Hicks TP and Conti F. Amino acids as the source of considerable excitation in cerebral cortex. Can J Physiol Pharmacol 74: 341-361 (1996).
23. Procter AW, Palmer AM, Francis PT, Lowe SL, Neary D, Murphy E, et al. (1988) Evidence of glutamatergic denervation and possible abnormal metabolism in Alzheimer's disease. J Neurochem 50: 790-802 (1988).
24. McGeer EG, Fibiger HC, McGeer PL and Wickson V. Aging and brain enzymes. Exp Gerontol 6: 391-396 (1971).
25. Maloteaux JM, Laterre EC, Laduron PM, Javoy-Agid F and Agid Y. Decrease of serotonin-S2 receptors in temporal cortex of patients with Parkinson's disease and progressive supranuclear palsy. Mov Disord 3: 255-262 (1988).
26. Palmer AM, Francis PT, Benton JS, Sims NR, Mann DM, Neary D, et al. Presynaptic serotonergic dysfunction in patients with Alzheimer's disease. J Neurochem 48: 8-15 (1987).
27. Trinchese F, Ninan I, LiUSAnd Arancio O. Alzheimer Aβ Increases Neurotransmitter Release and Blocks Synaptic Plasticity in Hippocampal Cultures. In: The 9th International Conference on Alzheimer's Disease and Related Disorders Abstr. Philadelphia, P3-323. (2004b).
28. Duff K, Eckman C, Zehr C, Yu X, Prada CM, Perez-Tur J, et al. Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature 383: 710-713 (1996).
29. Di Rosa G, Odrijin T, Nixon RA and Arancio O. Calpain inhibitors: a treatment for Alzheimer's disease. J Mol Neurosci 19: 135-141 (2002).
30. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, et al. Correlative memory deficits, Abeta elevation and amyloid plaques in transgenic mice. Science 274: 99-102 (1996).
31. Zucker RS. Short-term synaptic plasticity. Annu Rev Neurosci 12: 13-31 (1989).
32. Zucker RS and Regehr WG. Short-term synaptic plasticity. Annu Rev Physiol 64: 355-405 (2002).
33. Rosahl TW, Spillane D, Missler M, Herz J, Selig DK, Wolff JR, et al. Essential functions of synapsins I and II in synaptic vesicle regulation. Nature 375: 488-493 (1995).
34. Janz R, Sudhof TC, Hammer RE, Unni V, Siegelbaum SA and Bolshakov VY. Essential roles in synaptic plasticity for synaptogyrin I and synaptophysin I. Neuron 24: 687-700 (1999).
35. Fitzjohn SM, Morton RA, Kuenzi F, Rosahl TW, Shearman M, Lewis H, et al. Age-related impairment of synaptic transmission but normal long-term potentiation in transgenic mice that overexpress the human APP695SWE mutant form of amyloid precursor protein. J Neurosci 21: 4691-4698 (2001).
36. Moechars D, Dewachter I, Lorent K, Reverse D, Baekelandt V, Naidu A, et al. Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J Biol Chem 274: 6483-6492 (1999).
37. Larson J, Lynch G, Games D and Seubert P. Alterations in synaptic transmission and long-term potentiation in hippocampal slices from young and aged PDAPP mice. Brain Res 840: 23-35 (1999).
38. Hsia AY, Masliah E, McConlogue L, Yu GQ, Tatsuno G, Hu K, et al. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci USA 96: 3228-3233 (1999).
39. Arancio O, Zhang HP, Chen X, Lin C, Trinchese F, Puzzo D, et al. RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice. EMBO J 23(20): 4096-4105 (2004).
40. Jolas T, Zhang XS, Zhang Q, Wong G, Del Vecchio R, Gold L, et al. (2002) Long-term potentiation is increased in the CA1 area of the hippocampus of APP(swe/ind) CRND8 mice. Neurobiol Dis 11: 394-409 (2002).
41. Parent A, Linden DJ, Sisodia SS and Borchelt DR. (1999) Synaptic transmission and hippocampal long-term potentiation in transgenic mice expressing FAD-linked presenilin 1. Neurobiol Dis 6: 56-62 (1999).